DNA firm's blueprint for growth
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BY LUCY ROBERTS
Amersham International, which makes and supplies reagents to laboratories for DNA research, turned in a better second-half performance on the back of improved margins and expansion in Japan and the US.
Turnover for the health science group rose 3 per cent to pounds 333.6m for the year ending March, compared with pounds 324.2m in the same period last year.
Bill Castell, the group chief executive, said he was particularly pleased with the improved performance of the group's three main divisions - Life Science, Healthcare and Industrial Quality and Safety Assurance - in the second half of the year.
He said the main profit driver was the maintained focus on margin improvement and the decision to move away from the flat European market.
The mix of results disappointed the market, where shares were off 10p at 895p after an earlier low of 860p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments